<DOC>
	<DOC>NCT01208233</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also explore the relationship between PF-03049423 concentration and blood pressure.</brief_summary>
	<brief_title>Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke</brief_title>
	<detailed_description>The interim analysis for the POC study A9541004 demonstrated futility, and the study was stopped on the 6th of November 2013. There were no signals of serious safety concern.</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Diagnosis of ischemic stroke with an onset within 72 hours prior to start of study agent administration, male or female. Supratentorial ischemic stroke involving the cortex documented by neurological exam and confirmed by MRI. Stroke involving upper extremity. Subjects who received thrombolytic therapy may be enrolled and the use of antiplatelet is acceptable. Any other severe acute or chronic medical or psychiatric condition besides the stroke. Women of child bearing potential. Uncontrolled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Phase 2 Ischemic stroke Safety and efficacy</keyword>
</DOC>